BioSpace News Archive

Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) is pleased to advise that its subsidiary Algernon NeuroScience (AGN Neuro), has successfully completed dosing of the third and planned final cohort in its escalating dose Phase 1 clinical study of an intravenous (IV) formulation of AP-188 (“N,N-Dimethyltryptamine” or “DMT”).

RS BioTherapeutics is pleased to announce that it has appointed Michelle L. Shuffett, MD as its Senior Vice President of Medical and Scientific Affairs.

Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”) today announced top-line results from its pivotal Phase 3 REBUILD clinical trial evaluating the safety and efficacy of INOpulse® for the treatment of fibrotic Interstitial Lung Disease (fILD).

BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) today announces that as part of its ongoing broad-based collaboration with the Max Planck Society and the University Medical Center Gottingen (UMG), it has signed an exclusive worldwide license agreement to develop and commercialize VHH antibodies (NanoAbs) targeting Interleukin-17 (IL-17) as treatments for all potential indications, starting with psoriasis and psoriatic arthritis.

Lycia Therapeutics, Inc., a leader in extracellular protein degradation, announced that Aetna Wun Trombley, Ph.D., President and Chief Executive Officer of Lycia, will present a corporate overview at the Jefferies Healthcare Conference on Wednesday, June 7, 2023 at 2:00 pm ET in New York.

Labcorp (NYSE: LH), a leading global life sciences company, today announced Fortrea, the new company to be formed by the planned spin-off of Labcorp’s Clinical Development and Commercialization Services business, will host its inaugural Investor Day on Tuesday, June 6, 2023, in New York City at 9 a.m. ET.

Nanoscope Therapeutics Inc. today announced that management will present at the BIO International Convention, taking place June 5-8, 2023, in Boston, MA.

Chemomab Therapeutics Ltd. (Nasdaq: CMMB), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced changes to its executive leadership team and provided a corporate update.

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced updated results from BRACELET-1, a randomized phase 2 trial in HR+/HER2- metastatic breast cancer, which include data featured in an oral presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, as well as additional new data and analyses.

Compugen Ltd. today announced data to be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, showing that Compugen’s COM701 (anti-PVRIG) in triple combination with nivolumab and BMS-986207 (anti-TIGIT) demonstrated preliminary signal of durable anti-tumor activity in patients with recurrent, metastatic MSS endometrial cancer with a favorable safety profile.